Your browser is out of date

With an updated browser, you will have a better Medtronic website experience. Update my browser now.

×

Skip to main content

CLINICAL OUTCOMES EverFlex™ Peripheral Self-expanding Stent System

Alert Indications, Safety, and Warnings

DURABILITY II is the first controlled study to focus on treating long, complex lesions and to specifically test the performance of a single long stent in the superficial femoral artery. Read more about the DURABILITY II clinical study in these published, peer-reviewed journal articles.

Durability II — Primary 1-Year

The United States Study for Evaluating Endovascular Treatments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By using the Protégé EverFlex Nitinol Stent System II (DURABILITY II).

Matsumura JS, et al. J Vasc Surg. 2013;58:73-83.e1.

DURABILITY II — Primary 3-Year

A Single Stent Strategy in Patients with Lifestyle Limiting Claudication: 3-Year Results from the DURABILITY II Trial

Rocha-Singh KJ, et al. Catheter Cardiovasc Interv. 2015;86:164-170.

DURABILITY II — Gender 1-Year

The Impact of Sex on Angioplasty and Primary Stenting for Femoropopliteal Occlusive Disease: Results of the DURABILITY II Trial.

Tedros RO, et al. Ann Vasc Surg. 2014;28:1-9.

DURABILITY II — Gender 3-Year

Intermediate Outcomes of Femoropopliteal Stenting in Women: 3-Year Results of the DURABILITY II Trial.

Han DK, et al. Ann Vasc Surg. 2016;30:110-117.

DURABILITY 200 — Long Lesions

Results of the Protégé EverFlex 200-mm-long Nitinol Stent (ev3) in TASC C and D Femoropopliteal Lesions.

Bosiers M, et al. J Vasc Surg. 2011;54:1042-1050.

Peripheral Catalog

Choose from a full portfolio of peripheral products for endovascular interventions — products that help you reach your PAD patient treatment goals.

Download Catalog

Request More Information

Connect with Us

Contact Us

CardioVascular Lifeline Customer Support 24/7

+1 763-514-4000 (Worldwide)
rs.cstechsupport@medtronic.com